← Back to Search

Chelating Agent

Active/Active for Heart Attack (TACT2 Trial)

Phase 3
Waitlist Available
Led By Kevin J Anstrom, PhD
Research Sponsored by Mt. Sinai Medical Center, Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

TACT2 Trial Summary

This trial is testing whether chelation therapy and high-dose vitamins and minerals can prevent heart attacks in people with diabetes who have already had a heart attack.

Eligible Conditions
  • Heart Attack
  • Diabetes

TACT2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina

TACT2 Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Placebo/ ActiveActive Control2 Interventions
Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
Group II: Active/PlaceboActive Control1 Intervention
Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
Group III: Active/ActiveActive Control2 Interventions
Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
Group IV: Placebo/PlaceboPlacebo Group2 Interventions
Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)

Find a Location

Who is running the clinical trial?

Mt. Sinai Medical Center, MiamiLead Sponsor
18 Previous Clinical Trials
3,090 Total Patients Enrolled
National Center for Complementary and Integrative Health (NCCIH)NIH
832 Previous Clinical Trials
667,933 Total Patients Enrolled
Duke Clinical Research InstituteOTHER
63 Previous Clinical Trials
240,532 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential side effects associated with Active/Active use?

"Although it is still in Phase 3, there is already some evidence of Active/Active's efficacy as well as data from multiple rounds of testing supporting its safety; thus, we have given it a score of 3."

Answered by AI

Could you tell me if this clinical trial is still enrolling new patients?

"According to the latest update on clinicaltrials.gov, this study is not recruiting patients at this time. The trial was posted on October 1st, 2016 and was last edited on March 30th, 2022. Although this specific trial is not presently looking for candidates, there are 553 other trials that are."

Answered by AI
Recent research and studies
Circulation: Cardiovascular Quality and OutcomesJournal
The Effect of an Edta-based Chelation Regimen on Patients with Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)
Escolar, Esteban, Gervasio A. Lamas, Daniel B. Mark, Robin Boineau, Christine Goertz, Yves Rosenberg, Richard L. Nahin, et al.. 2014. “The Effect of an Edta-based Chelation Regimen on Patients with Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)”. Circulation: Cardiovascular Quality and Outcomes. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/circoutcomes.113.000663.
JamaJournal
Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients with Previous Myocardial Infarction
Lamas, Gervasio A., Christine Goertz, Robin Boineau, Daniel B. Mark, Theodore Rozema, Richard L. Nahin, Lauren Lindblad, et al.. 2013. “Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients with Previous Myocardial Infarction”. Jama. American Medical Association (AMA). doi:10.1001/jama.2013.2107.
American Heart JournalJournal
Design of the Trial to Assess Chelation Therapy (TACT)
Lamas, Gervasio A., Christine Goertz, Robin Boineau, Daniel B. Mark, Theodore Rozema, Richard L. Nahin, Jeanne A. Drisko, and Kerry L. Lee. 2012. “Design of the Trial to Assess Chelation Therapy (TACT)”. American Heart Journal. Elsevier BV. doi:10.1016/j.ahj.2011.10.002.
American Heart JournalJournal
EDTA Chelation Therapy Alone and in Combination with Oral High-dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy
Lamas, Gervasio A., Robin Boineau, Christine Goertz, Daniel B. Mark, Yves Rosenberg, Mario Stylianou, Theodore Rozema, et al.. 2014. “EDTA Chelation Therapy Alone and in Combination with Oral High-dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy”. American Heart Journal. Elsevier BV. doi:10.1016/j.ahj.2014.02.012.
~118 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top